Please provide your email address to receive an email when new articles are posted on . In this video, Alokkumar Jha, PhD, MSc, BE, spoke with Healio about key presentations from the American ...
Biohaven's (BHVN) first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel ...
Poster Presentation Title: Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II ...
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension ...
NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous ...
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results